Nilotinib Mylan

Nilotinib, the active ingredient in Nilotinib Mylan, is a tyrosine kinase inhibitor presented as an oral tablet for systemic use. It is prescribed for chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients, targeting malignant cell proliferation.

GNH USA supplies Nilotinib Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company provides regulatory‑qualified batches to major cancer treatment facilities across the EU and emerging markets, ensuring consistent quality and on‑time delivery.

Nilotinib is a tyrosine kinase inhibitor used in the management of hematologic malignancies driven by BCR‑ABL fusion proteins. - Chronic myeloid leukemia (CML): Reduces disease progression and improves survival in adult patients. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): Contributes to remission induction and maintenance therapy. - BCR‑ABL inhibitor‑resistant CML: Provides an alternative therapeutic option when prior TKIs are ineffective.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Rash: Mild to moderate skin eruptions. - Nausea: Transient gastrointestinal discomfort. - Diarrhea: Loose stools, often self‑limiting. - Elevated liver enzymes: Mild increases in ALT/AST.

Serious or Rare Side Effects: - Cardiovascular events: Myocardial infarction, stroke, or peripheral arterial disease. - Severe hepatic toxicity: Marked elevation of liver enzymes or hepatitis. - Pancreatitis: Inflammation of the pancreas presenting with abdominal pain. - QT interval prolongation: Potential for arrhythmias, especially with interacting drugs.

When prescribing nilotinib, clinicians should consider several precautionary measures to minimize risks. - Cardiac assessment: Evaluate baseline cardiovascular status and monitor for ischemic events. - Hepatic monitoring: Check liver function tests before initiation and periodically during therapy. - Electrolyte balance: Correct hypokalemia, hypomagnesemia, and hypocalcemia to reduce QT prolongation risk. - Drug interactions: Review concomitant medications for CYP3A4 inhibitors or QT‑prolonging agents. - Pregnancy and lactation: Avoid use in pregnant or breastfeeding women unless benefits outweigh risks. - Store at ambient temperature: Keep tablets below 25 °C in the original container, protected from moisture and light.

Nilotinib interacts with several medicines, requiring careful management to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: e.g., ketoconazole, can markedly increase nilotinib plasma levels. - Strong CYP3A4 inducers: e.g., rifampin, may substantially lower drug exposure. - QT‑prolonging drugs: e.g., amiodarone, increase risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: reduce absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents: Proton pump inhibitors may modestly decrease nilotinib exposure; timing adjustment recommended. - Statins metabolized by CYP3A4: e.g., simvastatin, may require dose reduction. - Anticoagulants: Warfarin may have altered INR; monitor coagulation parameters. - Herbal supplements: St. John’s wort can induce CYP3A4 and lower nilotinib levels.